The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin
- 28 February 1995
- journal article
- review article
- Published by Elsevier in Current Therapeutic Research
- Vol. 56 (2) , 111-128
- https://doi.org/10.1016/0011-393x(95)85036-8
Abstract
No abstract availableThis publication has 58 references indexed in Scilit:
- Efficacy and Safety of Fluvastatin, a New HMG CoA Reductase Inhibitor, in Elderly Hypercholesterolaemic WomenDrugs, 1994
- Addition of fibrates to simvastatin therapy in hyperlipidaemic patientsAtherosclerosis, 1992
- Effects of Combined Bezafibrate-Simvastatin Appraised in Healthy SubjectsThe Journal of Clinical Pharmacology, 1992
- Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatinThe American Journal of Cardiology, 1991
- A Comparative Review of the Adverse Effects of Treatments for HyperlipidaemiaDrug Safety, 1991
- Regulation of the mevalonate pathwayNature, 1990
- Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDMDiabetes, 1989
- HMG CoA Reductase InhibitorsDrugs, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine.CHEMICAL & PHARMACEUTICAL BULLETIN, 1986